Press Release

First results from POSITIVE study: Young women with breast can safely have a baby

BIGagainstBC 6 December 2022

AURORA, the first international molecular screening programme for metastatic breast cancer, presented at IMPAKT Breast Cancer Conference

Monet St Juste 23 September 2022

New Treatment Option for Young Women with Hormone-Sensitive Breast Cancer

Monet St Juste 23 September 2022

ALTTO Test of Dual HER2 Blockade Finds Single Agent – Trastuzumab – Remains the Gold Standard

Monet St Juste 23 September 2022

Opening of international PANACEA study of patients with HER2+ breast cancer

Monet St Juste 23 September 2022

Belgian Dr. Martine Piccart has received prestigious international Brinker Award for Scientific Distinction in Clinical Research

Monet St Juste 23 September 2022

Pfizer Awards Breast International Group (BIG) $1 Million Research Grant to Support Non‐Drug Related Breast Cancer Research

Monet St Juste 23 September 2022

New England Journal of Medicine” publishes results of MINDACT clinical trial The 70-gene test (Mammaprint®) can significantly reduce use of chemotherapy among breast cancer patients and has the potential to change clinical practice: 46% of early stage breast cancer patients classified as high-risk by traditional methods can avoid chemotherapy

Monet St Juste 23 September 2022

Phase III APHINITY study shows Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy

Monet St Juste 23 September 2022

APHINITY study shows Roche’s Perjeta®-based regimen reduced the risk of invasive cancer returning compared to Herceptin® and chemotherapy in HER2-positive early breast cancer

Monet St Juste 23 September 2022